Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype.
Publication
, Journal Article
Piccini, JP; Dufton, C; Carroll, IA; Healey, JS; Abraham, WT; Khaykin, Y; Aleong, R; Krueger, SK; Sauer, WH; Wilton, SB; Rienstra, M; White, M ...
Published in: Circ Arrhythm Electrophysiol
August 2021
[Figure: see text].
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Circ Arrhythm Electrophysiol
DOI
EISSN
1941-3084
Publication Date
August 2021
Volume
14
Issue
8
Start / End Page
e009591
Location
United States
Related Subject Headings
- Time Factors
- Receptors, Adrenergic, beta-1
- Propanolamines
- Male
- Humans
- Heart Failure
- Genotype
- Follow-Up Studies
- Female
- Electrocardiography
Citation
APA
Chicago
ICMJE
MLA
NLM
Piccini, J. P., Dufton, C., Carroll, I. A., Healey, J. S., Abraham, W. T., Khaykin, Y., … Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Trial Investigators*, . (2021). Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol, 14(8), e009591. https://doi.org/10.1161/CIRCEP.120.009591
Piccini, Jonathan P., Christopher Dufton, Ian A. Carroll, Jeff S. Healey, William T. Abraham, Yaariv Khaykin, Ryan Aleong, et al. “Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype.” Circ Arrhythm Electrophysiol 14, no. 8 (August 2021): e009591. https://doi.org/10.1161/CIRCEP.120.009591.
Piccini JP, Dufton C, Carroll IA, Healey JS, Abraham WT, Khaykin Y, et al. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol. 2021 Aug;14(8):e009591.
Piccini, Jonathan P., et al. “Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype.” Circ Arrhythm Electrophysiol, vol. 14, no. 8, Aug. 2021, p. e009591. Pubmed, doi:10.1161/CIRCEP.120.009591.
Piccini JP, Dufton C, Carroll IA, Healey JS, Abraham WT, Khaykin Y, Aleong R, Krueger SK, Sauer WH, Wilton SB, Rienstra M, van Veldhuisen DJ, Anand IS, White M, Camm AJ, Ziegler PD, Marshall D, Bristow MR, Connolly SJ, Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Trial Investigators*. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol. 2021 Aug;14(8):e009591.
Published In
Circ Arrhythm Electrophysiol
DOI
EISSN
1941-3084
Publication Date
August 2021
Volume
14
Issue
8
Start / End Page
e009591
Location
United States
Related Subject Headings
- Time Factors
- Receptors, Adrenergic, beta-1
- Propanolamines
- Male
- Humans
- Heart Failure
- Genotype
- Follow-Up Studies
- Female
- Electrocardiography